Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Pevonedistat Plus Ibrutinib Showcases Preliminary Efficacy and Tolerability in CLL and MCL

October 21st 2021

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Implementable Changes Could Improve QOL With Radiation-Related Mucositis in Head and Neck Cancer

October 20th 2021

Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.

Trial Launches to Evaluate Novel ADC in Previously Treated HER2+ Breast Cancer

October 19th 2021

The phase 2 ACE-Breast03 trial has been launched to evaluate the efficacy and safety of ARX788, an investigational antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer who have progressed on prior HER2-directed therapies.

New Subcutaneous, Oral, and Intravenous Therapies Transform Treatment in Early-Stage HER2+ Breast Cancer

October 18th 2021

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium

October 13th 2021

Harry Paul Erba, MD, PhD, spotlights practice-changing data that emerged in recent years in hematologic malignancies and speaks to remaining questions, particularly with CAR T-cell therapy, in each paradigm.

Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer

October 12th 2021

With new therapeutic options, such as enfortumab vedotin-ejfv and, available to treat patients with locally advanced or metastatic urothelial cancer who require second- or third-line therapy, early detection of disease progression is critical.

Chemotherapy-Free Options Expand the Scope of Treatment in Leukemia and Lymphoma

October 12th 2021

Across the paradigms of leukemias and lymphomas, novel therapies—such as BTK inhibitors, PI3K inhibitors, time-limited therapies, and even CAR T-cell therapies—have transformed the treatment of patients and prolonged survival without the need for chemotherapy.

New Surgical and Systemic Approaches Enable Earlier Intervention in CRC With Liver Metastases

October 8th 2021

Shikha Jain, MD, FACP, and Mario Spaggiari, MD, highlight key advancements made in the treatment of patients with colorectal cancer and liver metastases, patient and disease factors to consider for surgical and systemic treatment, and the importance of multidisciplinary care for this population.

Retroperitoneal Surgical Resection Requires Multipronged Decision Making in Sarcoma

October 8th 2021

Retroperitoneal surgery for patients with sarcoma requires nuanced decision making that incorporates technical aspects of resection, as well as patient-related and tumor-related factors, according to a presentation given during the 2021 ESMO Congress.

Management Strategies Shift Across NSCLC, Small Cell Lung Cancer, and Mesothelioma

October 7th 2021

As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.

Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC

October 7th 2021

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

Novel Therapies Shake Up the Spectrum of Breast Cancer Treatment

October 6th 2021

Zahi Mitri, MD, MS, discusses recent advancements made across the breast cancer paradigm and spotlighted key data that led to the integration of novel agents into the armamentariums.

Amivantamab Plus Lazertinib Demonstrates Activity After Osimertinib and/or Chemo in EGFR-Mutant NSCLC

October 5th 2021

Amivantamab-vmjw in combination with lazertinib demonstrated significant clinical activity with durable responses in patients with EGFR-mutated non–small cell lung cancer who had progressed on osimertinib.

ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma

October 4th 2021

A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.

Molecular Testing and Multidisciplinary Care Is A Necessity in Metastatic NSCLC

October 1st 2021

Although adjuvant targeted therapy options are reserved for patients with EGFR-mutated non–small cell lung cancer, molecular testing is a critical step in the treatment of all patients with metastatic disease, where multiple driver mutations are associated with FDA-approved therapeutics.

Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers

September 30th 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

Later-Line Therapy in Metastatic CRC Calls for Safety Considerations in Refined Decision Making

September 30th 2021

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

Checkpoint Inhibitors Demonstrate Broad Reach in GU Cancers

September 28th 2021

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

Prolonged Overall Survival Observed With Oral Decitabine/Cedazuridine in MDS and CMML

September 24th 2021

Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24th 2021

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.